loading...| Preferred Name |
Dalbavancin |
|
| Synonyms |
|
|
| Definitions |
A second-generation, semi-synthetic lipoglycopeptide antibiotic, with bactericidal activity against a variety of gram-positive bacteria. Upon administration, dalbavancin binds, at a site different from that of penicillins and cephalosporins, tightly to the D-alanyl-D-alanine portion of peptidoglycan chains, thereby preventing peptidoglycan elongation and interfering with bacterial cell wall synthesis. This leads to activation of bacterial autolysins and induces cell wall lysis. |
|
| ID |
http://purl.obolibrary.org/obo/NCIT_C116741 |
|
| CAS_Registry |
171500-79-1 |
|
| code |
C116741 |
|
| Contributing_Source |
CTRP FDA |
|
| definition |
A second-generation, semi-synthetic lipoglycopeptide antibiotic, with bactericidal activity against a variety of gram-positive bacteria. Upon administration, dalbavancin binds, at a site different from that of penicillins and cephalosporins, tightly to the D-alanyl-D-alanine portion of peptidoglycan chains, thereby preventing peptidoglycan elongation and interfering with bacterial cell wall synthesis. This leads to activation of bacterial autolysins and induces cell wall lysis. |
|
| Display_Name |
Dalbavancin |
|
| FDA_UNII_Code |
808UI9MS5K |
|
| in_subset |
http://purl.obolibrary.org/obo/NCIT_C63923 http://purl.obolibrary.org/obo/NCIT_C176424 |
|
| label |
Dalbavancin |
|
| NCI_Drug_Dictionary_ID |
682691 |
|
| PDQ_Closed_Trial_Search_ID |
682691 |
|
| PDQ_Open_Trial_Search_ID |
682691 |
|
| Preferred_Name |
Dalbavancin |
|
| prefixIRI |
NCIT:C116741 |
|
| prefLabel |
Dalbavancin |
|
| Semantic_Type |
Pharmacologic Substance |
|
| UMLS_CUI |
C0911853 |
|
| subClassOf |